FACULTY DISCLOSURES

As a provider accredited by the Accreditation Council for Continuing Medical Education, it is the policy of Research To Practice to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:

Faculty Affiliations and Disclosures

	Adam M Brufsky, MD, PhD Assistant Professor of Medicine, University of Pittsburgh Member, University of Pittsburgh Cancer Institute Director, Comprehensive Breast Cancer Center Associate Division Chief, University of Pittsburgh, Department of Medicine, Division of Hematology/Oncology Pittsburgh, Pennsylvania
Grants/Research Support, Consultant, and Honorarium: AstraZeneca Pharmaceuticals LP, Aventis Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech BioOncology
	Daniel R Budman, MD Associate Chief, Don Monti Division of Medical Oncology Division of Hematology, North Shore University Hospital Professor of Medicine, New York University Manhasset, New York
Grants/Research Support: Aventis Pharmaceuticals Inc, Eisai Inc, Eli Lilly and Company, Novartis Pharmaceuticals, Pfizer Inc, Roche Laboratories Inc Consultant: Eisai Inc Honorarium: Amgen Inc, Aventis Pharmaceuticals Inc, Pfizer Inc, Roche Laboratories Inc Speakers Bureau: Aventis Pharmaceuticals Inc, Pfizer Inc
	G Thomas Budd, MD Professor of Medicine Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Cleveland Clinic Foundation Cleveland, Ohio
Grants/Research Support: AstraZeneca Pharmaceuticals LP, Aventis Pharmaceuticals Inc, Novartis Pharmaceuticals, Pfizer Inc, Immunicon Corporation Speakers Bureau: AstraZeneca Pharmaceuticals LP, Aventis Pharmaceuticals Inc, Genentech BioOncology, Novartis Pharmaceuticals, Pfizer Inc
	Hyman B Muss, MD Professor of Medicine, University of Vermont Director of Hematology/Oncology, Fletcher Allen Health Care Burlington, Vermont
Grants/Research Support: AstraZeneca Pharmaceuticals LP, Aventis Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Merck and Company Inc, Ortho Biotech Products LP, Pfizer Inc, Tibotec Inc Stock Shareholder: Amgen Inc, Enzon Pharmaceuticals

* Discontinued by manufacturer

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.